Ionis Pharmaceuticals stock to rise 5% by July 31, 2026

Ionis Pharmaceuticals is set to report earnings in the coming weeks, and given its strong pipeline and recent clinical trial updates, the stock is positioned to benefit from positive investor sentiment. Analysts expect a beat on earnings and revenue.

earnings · Prediction Market

Implied probability (Yes)

70%

Closes

2026-07-31

More earnings markets

• Driving instructor revenue drops 15% in Q3 2027 due to test booking changes — 68% Yes
• Forum AI raises $50M+ in Series B funding by 2027-03-31 — 60% Yes
• Anthropic's compute deal with xAI will underperform revenue targets by Q4 2026 — 70% Yes
• Titleist sells more clubs than Callaway in 2026 — 72% Yes
• Sadi Thermal Machines secures $50M+ funding round by 2027 — 70% Yes
• Lime achieves profitability within 12 months post-IPO — 55% Yes
• SK Hynix ADRs to price at or above midpoint range by July 10 — 75% Yes
• SpaceX AI division revenue exceeds $500M in 2025 — 65% Yes

Browse all earnings markets →